![]() |
市場調査レポート
商品コード
1520503
ニコチンガム市場レポート:タイプ、用途、流通チャネル、地域別、2024年~2032年Nicotine Gum Market Report by Type, Application, Distribution Channel, and Region 2024-2032 |
||||||
カスタマイズ可能
|
ニコチンガム市場レポート:タイプ、用途、流通チャネル、地域別、2024年~2032年 |
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2~3営業日
|
世界のニコチンガム市場規模は2023年に16億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに24億米ドルに達し、2024年から2032年の間に4.21%の成長率(CAGR)を示すと予測しています。世界市場を牽引している要因には、禁煙への取り組みや健康意識の高まり、手軽な市販(OTC)ニコチン代替療法への需要の高まり、製品の有効性を高めるための技術革新など、さまざまなものがあります。
主な市場促進要因:喫煙に伴う健康リスクに対する意識の高まりと、世界の禁煙へのさまざまな取り組みが成長促進要因として作用しています。
主要市場動向:市販(OTC)ニコチン代替療法の需要が増加しています。これは、禁煙を目指す人々の間で製品の利便性と入手しやすさが向上していることと相まって、市場の成長を支えています。
地理的動向:報告書によると、北米は健康志向の消費者の増加により、市場で主導的な地位を占めています。
競合情勢:ニコチンガム業界の主要企業は、British American Tobacco、Cambrex Corporation、GlaxoSmithKline、ITC Limited、Johnson &Johnson Services、Novartis、Perrigo、Pfizer、武田薬品工業などです。
課題と機会:課題としては、禁煙補助剤にまつわる社会的スティグマを克服し、禁煙プロセスにおけるニコチンガムの役割について適切な教育を行う必要があります。それにもかかわらず、ニコチンガム市場最近の機会としては、喫煙に関連する健康問題に対処するための技術の進歩や企業間の協力が挙げられます。
禁煙への取り組みと健康意識
喫煙を減らすための世界の取り組みが、健康意識の高まりとともに市場拡大を後押ししています。喫煙に関連する健康リスクに対する意識が高まるにつれて、人々は禁煙のための効果的な戦略を積極的に模索しています。ニコチンガムは禁煙補助剤であり、ニコチンを徐々に放出することで禁断症状を抑えることができます。さらに、ヘルスケア機関や規制当局による様々な禁煙プログラムが、ニコチンガムの需要にとって好ましい雰囲気を作り出しています。公衆衛生の重視と禁煙への継続的な取り組みにより、禁煙治療に不可欠な要素としてこのガムが受け入れられるようになってきたことが、市場の成長を後押ししています。2023年4月11日、ニール・オブライエン保健相は、喫煙率削減と未成年者VAPEへの取り組みに関する政府計画についてPolicy Exchangeで講演を行った、
OTCニコチン代替療法の需要拡大
IMARCグループによると、2023年、世界のOTC医薬品産業の規模は1,687億米ドルでした。市場を推進している主な要因の1つは、OTCニコチン置換薬に対する需要の高まりです。このガムは、処方箋なしで自己投与が可能な、簡単に入手できるOTCソリューションです。このガムが、医療の助けを求めずに禁煙しようとする人々の最良の選択肢として人気があるのは、その入手のしやすさと使いやすさによる。人々は健康管理に積極的になっており、これは前向きなニコチンガム市場の展望を提供しています。さらに2024年1月24日、オディシャ州カッタックにあるシュリ・ラム・チャンドラ・バンジャ(SCB)歯科大学・病院で実施された臨床試験で、行動療法と組み合わせた場合のニコチン置換療法(NRT)の顕著な有効性が発表され、禁煙の取り組みに大きなブレークスルーがもたらされました。
技術の進歩と製品の革新
ニコチン置換療法の処方と投与における継続的な技術改良と製品革新が、市場の成長を後押ししています。ニコチンガム企業は、製品の有効性とユーザー体験を向上させるために研究開発(R&D)活動に資金を費やしています。ユーザーは、強化されたフレーバーやユニークなデリバリー・システムのような技術革新により、これらのガムを採用しています。加えて、ニコチン中毒と禁断症状のプロセスに対する理解が深まったことは、より効率的なガムの製剤の作成に役立っています。より効率的な禁煙ソリューションに対する需要の高まりが、ニコチンガム市場の成長を後押ししています。これに加え、同市場の企業は公認当局から製品承認を取得しています。例えば、Perrigo Company plc(PRGO)は、2023年5月16日にニコチンコーティングミントロゼンジ2mgおよび4mg OTCの最終承認を食品医薬品局(FDA)から取得しました。この製品は、禁煙を試みる消費者の禁断症状を軽減するのに役立ちます。さらに、ニコレットコーティングアイスミントロゼンジに匹敵する製品として、小売店のストアブランドラベルで販売される予定です。
The global nicotine gum market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.21% during 2024-2032. There are various factors that are driving the global market, which include smoking cessation initiatives and heightened health awareness, rising demand for convenient over the counter (OTC) nicotine replacement therapies, and technological innovations for enhancing product efficacy.
Major Market Drivers: The increasing awareness about health risks associated with smoking, along with various smoking cessation initiatives worldwide, are acting as growth-inducing factors.
Key Market Trends: There is a rise in the demand for over the counter (OTC) nicotine replacement therapies. This, coupled with the enhanced convenience and accessibility of the product among individuals seeking to quit smoking, are supporting the market growth.
Geographical Trends: According to the report, North America enjoys a leading position in the market due to the rising number of health-conscious consumers.
Competitive Landscape: Top players in the nicotine gum industry are British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company, among many others.
Challenges and Opportunities: Challenges include the need to overcome social stigmas associated with smoking cessation aids and ensure proper education about the role of nicotine gum in the quitting process. Nonetheless, nicotine gum market recent opportunities are technological advancements and collaborations among companies to address smoking-related health issues.
Smoking Cessation Initiatives and Health Awareness
Global efforts to reduce smoking, along with rising health awareness, are propelling the market expansion. People are actively looking for effective strategies to quit smoking as awareness about health risks connected with smoking increases among them. Nicotine gum is a smoking cessation aid that helps users manage the symptoms of withdrawal by releasing nicotine gradually and under control. In addition, various smoking cessation programs by healthcare organizations and regulatory authorities has created a favorable atmosphere for nicotine gum demand. The rising acceptance of this gum as an essential component of smoking cessation treatments due to the emphasis on public health and the ongoing efforts to eliminate smoking is impelling the market growth. On 11 April 2023, Neil O'Brien, Health Minister, delivered a speech at Policy Exchange on government plans to cut smoking rates and tackle underage vaping,
Growing Demand for OTC Nicotine Replacement Therapies
As per the IMARC Group, in 2023, the size of the OTC medication industry worldwide was US$ 168.7 Billion. One of the main factors propelling the market is the rising demand for OTC nicotine replacement medicines. This gum is an easily available OTC solution that enables users to self-administer therapy without a prescription. This gum's popularity as a top option for people trying to stop smoking without seeking medical help is due to its accessibility and ease of usage. People are becoming more proactive in managing their health, which is offering a positive nicotine gum market outlook. Furthermore, on 24 January 2024, in a significant breakthrough for tobacco cessation efforts, a clinical trial conducted at Sri Ram Chandra Bhanja (SCB) Dental College and Hospital in Cuttack, Odisha, unveiled the remarkable efficacy of nicotine replacement therapy (NRT) when combined with behavioral therapy.
Technological Advancements and Product Innovation
Continuous technological improvements and product innovations in the formulation and administration of nicotine replacement therapies are bolstering the market growth. Nicotine gum companies are spending money on research and development (R&D) activities to enhance the effectiveness of product as well as user experience. Users are adopting these gums owing to innovations like enhanced flavors and unique delivery systems. In addition, enhanced understanding of nicotine addiction and withdrawal processes are benefiting in the creation of gum formulations that are more efficient. The escalating demand for more efficient smoking cessation solutions is bolstering the nicotine gum market growth. Besides this, companies in the market are getting product approvals from the recognized authorities. For instance, Perrigo Company plc (PRGO) received final approval from the Food Drug Administration (FDA) for nicotine coated mint lozenges 2 mg and 4 mg OTC on 16 May 2023. The product helps in reducing withdrawal symptoms in consumers who are trying to quit smoking. Moreover, it will be marketed under retailer's store brand labels as a comparable offering to Nicorette coated ice mint lozenge.
IMARC Group provides an analysis of the key nicotine gum market trends in each market segment, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, application, and distribution channel.
The report has provided a detailed breakup and analysis of the market based on the type. This includes 2 mg nicotine gum, 4 mg nicotine gum, and 6 mg nicotine gum. According to the report, 2 mg nicotine gum represented the largest segment.
Those looking to cut back on their nicotine intake during their journey to quit smoking can find 2 mg category a suitable choice. 2mg nicotine gum is an ideal alternative for controlling withdrawal symptoms while progressively weaning off nicotine dependence, making it the perfect choice among light to moderate smokers. Furthermore, it is advised for people who need a step-down strategy and in the early phases of quitting in order to enable a more regulated shift to a life free of nicotine.
Withdrawal Clinics
Medical Practice
Individual Smokers
Others
Medical practice holds the largest share of the industry
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes withdrawal clinics, medical practice, individual smokers, and others. According to the report, medical practice accounted for the largest market share.
Nicotine gums are used in more comprehensive smoking cessation programs in medical settings. Physicians may recommend this gum to patients as part of individualized smoking cessation regimens or during routine consultations. The progressive and regulated release of nicotine from the gum is consistent with evidence-based therapies. In the medical practice application, the importance of healthcare professionals in helping people quit is emphasized, along with the health advantages and individualized assistance that come with using nicotine gum.
Retail Pharmacies
Specialty Stores
Online Stores
Others
Retail pharmacies represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacies, specialty stores, online stores, and others. According to the report, retail pharmacies represented the largest segment.
Nicotine gums are readily available at retail pharmacies. Consumers in search of smoking cessation products can easily locate them in close proximity to their homes. This gum is easily available and pharmacists can offer their advice related to medication, which makes it a favored option for those seeking person-to-person support and quick access to quit smoking products.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest nicotine gum market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for nicotine gum.
North America stands as a significant market due to robust smoking cessation efforts, heightened health awareness, and a substantial consumer base. The region has a well-established healthcare infrastructure and proactive regulatory measures that contribute to the popularity of these gums as a preferred smoking cessation aid. In addition, there is an increase in the number of individuals seeking effective solutions to quit smoking in the North America region. Besides this, the wide availability of these gum across various distribution channels including retail pharmacies and online stores, assists in increasing nicotine gum market revenue. On 18 March 2024, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the completion of a 5-year, US$ 100-Million-dollar investment strategy, one year ahead of schedule. The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, which will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the nicotine gum industry include British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Key players in the market are engaging in strategic initiatives that are focused on product innovation, marketing, and collaborative efforts. Continuous R&D investments by key manufacturers aim to enhance the effectiveness and appeal of the product formulations. These companies leverage technological advancements to create novel delivery mechanisms, improved flavors, and better taste masking, meeting consumer preferences and driving market growth. Moreover, robust marketing campaigns and partnerships with healthcare organizations contribute to the rising awareness about smoking cessation benefits among individuals while expanding the consumer base. Collaborative efforts between industry stakeholders and regulatory bodies ensure compliance with health standards and foster a positive market environment. On 3 July 2023, Haleon, the world's biggest standalone consumer health business, explored the sale of its nicotine gum business as it aims to streamline its business. The company is working with an adviser to find potential suitors for its Nicotinell brand of nicotine gum, which could be worth about US$ 800 Million in sales.